Olanzapine in the Treatment of Pathological Gambling: A Negative Randomized Placebo-Controlled Trial
J Clin Psychiatry 2008;69(3):433-440
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: Pathological gambling is associated with bipolar
disorder and dopamine dysfunction. Olanzapine is a second-generation
antipsychotic with mood-stabilizing properties and antagonistic activity at
several dopamine receptors. The purpose of this study was to evaluate
olanzapine in the treatment of pathological gambling.
Method: In this 12-week, single-center, randomized,
double-blind, placebo-controlled, flexible-dose (2.5-15 mg/day) trial, 42
outpatients with pathological gambling by DSM-IV-TR criteria received
olanzapine (N = 21) or placebo (N = 21). The primary outcome measure was the
Pathological Gambling Adaptation of the Yale-Brown Obsessive Compulsive Scale (PG-YBOCS).
The primary analysis of efficacy was a longitudinal analysis of the
intent-to-treat sample, with treatment-by-time interaction as the effect
measure. Subjects were enrolled from June 2, 2000, through November 28, 2005.
Results: Compared with placebo, olanzapine was associated with
a similar rate of reduction in total scores on the PG-YBOCS scale, as well as
in gambling episodes/week, hours gambled/week, and Clinical Global
Impressions-Severity of Illness scale scores. The mean (SD) olanzapine daily
dose at endpoint evaluation was 8.9 (5.2) mg/day. Eleven subjects (52%)
receiving olanzapine and 6 (29%) receiving placebo discontinued prematurely; 3
subjects receiving olanzapine and 2 receiving placebo discontinued because of
adverse events. Events causing olanzapine discontinuation were pneumonia,
sedation, and hypomania.
Conclusion: Olanzapine was not superior to placebo in the
short-term treatment of pathological gambling. It was also associated with a
high discontinuation rate.